From 2000 until 2014 Dr Daniels held various management positions at Bristol-Myers Squibb Pharmaceutical group, US, most recently as Senior Vice President for Global Development and Medical Affairs and as a member of the senior management team. From 1996 until 2000 Dr Daniels held a series of leadership positions at Merck Research Laboratories, US. Dr Daniels is senior advisor with the Boston Consulting Group and venture partner with 5AM Venture Management, LLC, both in the US. Dr Daniels has a M.D. from Washington University, St. Louis, US (1987) and a B.S. in Life Sciences from Massachusetts Institute of Technology, Cambridge, US (1981). Dr Daniels also has a M.A. in Metabolism and Nutritional Biochemistry from Massachusetts Institute of Technology, Cambridge, US (1981). Dr Daniels was first elected to the Board of Novo Nordisk A/S in 2016 and has most recently been re-elected in March 2017. His term as a board member expires in March 2018. In March 2017, the Board of Directors of Novo Nordisk A/S assessed that Dr Daniels is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen. In January 2017, the Board of Directors also assessed that the special competencies possessed by Dr Daniels that are important for the performance of his duties are his extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutics areas within the pharmaceutical industry, especially in the US. Dr Daniels is a male US national, born February 1959. From 2000 until 2014 Dr Daniels held various management positions at Bristol-Myers Squibb Pharmaceutical group, US, most recently as Senior Vice President for Global Development and Medical Affairs and as a member of the senior management team. From 1996 until 2000 Dr Daniels held a series of leadership positions at Merck Research Laboratories, US. Dr Daniels is senior advisor with the Boston Consulting Group and venture partner with 5AM Venture Management, LLC, both in the US. Dr Daniels has a M.D. from Washington University, St. Louis, US (1987) and a B.S. in Life Sciences from Massachusetts Institute of Technology, Cambridge, US (1981). Dr Daniels also has a M.A. in Metabolism and Nutritional Biochemistry from Massachusetts Institute of Technology, Cambridge, US (1981). Dr Daniels was first elected to the Board of Novo Nordisk A/S in 2016 and has most recently been re-elected in March 2017. His term as a board member expires in March 2018. In March 2017, the Board of Directors of Novo Nordisk A/S assessed that Dr Daniels is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen. In January 2017, the Board of Directors also assessed that the special competencies possessed by Dr Daniels that are important for the performance of his duties are his extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutics areas within the pharmaceutical industry, especially in the US. Dr Daniels is a male US national, born February 1959.

Pathology